Delivery technologies for T cell gene editing: Applications in cancer immunotherapy
Ella S. Atsavapranee,
Margaret M. Billingsley,
Michael J. Mitchell
Affiliations
Ella S. Atsavapranee
Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA
Margaret M. Billingsley
Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA
Michael J. Mitchell
Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Corresponding author at: Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
While initial approaches to adoptive T cell therapy relied on the identification and expansion of rare tumour-reactive T cells, genetic engineering has transformed cancer immunotherapy by enabling the modification of primary T cells to increase their therapeutic potential. Specifically, gene editing technologies have been utilized to create T cell populations with improved responses to antigens, lower rates of exhaustion, and potential for use in allogeneic applications. In this review, we provide an overview of T cell therapy gene editing strategies and the delivery technologies utilized to genetically engineer T cells. We also discuss recent investigations and clinical trials that have utilized gene editing to enhance the efficacy of T cells and broaden the application of cancer immunotherapies.
